Johnson & Johnson Acquires Halda Therapeutics for $3.05 Billion to Add RIPTAC Cancer Drug Platform
Johnson & Johnson is acquiring Halda Therapeutics for $3.05 billion in cash.
The deal centers on Halda's RIPTAC™ platform, a novel approach to targeted protein degradation for cancer therapy.
Halda's lead drug, HLD-0915, showed positive Phase 1/2 results in advanced prostate cancer.
The RIPTAC platform may also be applied to breast, lung, and other solid tumors, as well as non-cancer diseases.
The acquisition is expected to close in the coming months, pending regulatory approval and customary closing conditions.
Halda emerged from stealth in 2023 and has no other clinical assets beyond HLD-0915 and preclinical programs.
J&J aims to bolster its oncology portfolio and address drug resistance with Halda's technology.